Company Description
Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates.
The company's therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.
It also develops INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company.
Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.
Country | United States |
Founded | 2010 |
IPO Date | Aug 19, 2020 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 172 |
CEO | Mark Paul Lappe |
Contact Details
Address: 11025 N. Torrey Pines Road, Suite 200 La Jolla, California 92037 United States | |
Phone | (858) 795-4220 |
Website | inhibrx.com |
Stock Details
Ticker Symbol | INBX |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $17.00 |
CIK Code | 0001739614 |
CUSIP Number | 45720L107 |
ISIN Number | US45720L1070 |
Employer ID | 82-4257312 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Mark Paul Lappe | Founder, Chairman, President and Chief Executive Officer |
Dr. Brendan P. Eckelman Ph.D. | Founder and Chief Scientific Officer |
Kelly Devine Deck B.S., CPA, M.S. | Executive Vice President and Chief Financial Officer |
Quinn L. Deveraux | Founder |
Dr. Ashraf Amanullah | Executive Vice President and Chief Technical Operations Officer |
Leah Pollema J.D. | Vice President, Corporate Secretary and General Counsel |
Dr. Charbel Helaihel Pharm.D. | Vice President of Marketing and Commercial Planning |
Jeffrey J. Jensen | Executive Vice President and Chief Clinical Operations Officer |
David Matly M.B.A. | Executive Vice President and Chief Commercial and Business Development Officer |
Dr. Carlos Bais Ph.D. | Executive Vice President of Translational Sciences |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 26, 2024 | 144 | Filing |
Mar 22, 2024 | 144 | Filing |
Mar 21, 2024 | 144 | Filing |
Mar 20, 2024 | 144 | Filing |
Mar 13, 2024 | 144 | Filing |
Mar 13, 2024 | 144 | Filing |
Mar 12, 2024 | 144 | Filing |
Mar 12, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Mar 12, 2024 | 8-K | Current Report |
Mar 11, 2024 | 144 | Filing |